Oruka Therapeutics Reports Positive Week 28 Data for ORKA-001 in Plaque Psoriasis; Shares Fall

Oruka Therapeutics, Inc. (ORKA) announced positive Week 28 results from its Phase 2a EVERLAST-A trial of ORKA-001 in patients with moderate-to-severe plaque psoriasis on September 23, 2026. Despite the data readout, the company's stock declined. The trial evaluated ORKA-001 in patients with moderate-to-severe plaque psoriasis. The company characterized the results as positive. Additional efficacy and safety data from the study were not disclosed in the announcement. Shares of ORKA fell following the release. The reason for the negative market reaction was not immediately specified.